Our top pick for
Kronos Bio, Inc is an other business based in the US. Kronos Bio shares (KRON) are listed on the NASDAQ and all prices are listed in US Dollars. Kronos Bio employs 61 staff and has a market cap (total outstanding shares value) of USD$1.7 billion.
|52-week range||USD$25.5006 - USD$39.605|
|50-day moving average||USD$29.4762|
|200-day moving average||USD$30.665|
|Wall St. target price||USD$43.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.7 billion|
TTM: trailing 12 months
There are currently 2.2 million Kronos Bio shares held short by investors – that's known as Kronos Bio's "short interest". This figure is 8.3% up from 2.0 million last month.
There are a few different ways that this level of interest in shorting Kronos Bio shares can be evaluated.
Kronos Bio's "short interest ratio" (SIR) is the quantity of Kronos Bio shares currently shorted divided by the average quantity of Kronos Bio shares traded daily (recently around 110264.92462312). Kronos Bio's SIR currently stands at 19.9. In other words for every 100,000 Kronos Bio shares traded daily on the market, roughly 19900 shares are currently held short.
To gain some more context, you can compare Kronos Bio's short interest ratio against those of similar companies.
However Kronos Bio's short interest can also be evaluated against the total number of Kronos Bio shares, or, against the total number of tradable Kronos Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kronos Bio's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Kronos Bio shares in existence, roughly 40 shares are currently held short) or 0.0566% of the tradable shares (for every 100,000 tradable Kronos Bio shares, roughly 57 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kronos Bio.
Find out more about how you can short Kronos Bio stock.
We're not expecting Kronos Bio to pay a dividend over the next 12 months.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.